1/ Pleased to share our review, published today Nature Rev Immunol, highlighting how biomolecular condensates enhance the precision and flexibility of gene regulatory networks that guide fate decisions during normal and pathological immune cell development. nature.com/articles/s4157…

🚨Excited to share our latest work, now out in Nature Biotechnology ! We introduce SEED-Selection, a powerful method that enables high-efficiency enrichment of T cells edited at multiple loci in a single step 🧵👇 🔗 nature.com/articles/s4158…

Expanding the engineered Treg universe! A treat to write this Commentary Molecular Therapy Family of Journals with Russell Cochrane and Eva Allen on T cell receptor fusion construct (TRuC) Tregs! 🛻 Congratulations Dimitrios L. Wagner on the exciting development! cell.com/molecular-ther… cell.com/molecular-ther…

Gene editing of CD3 epsilon to redirect regulatory T cells for adoptive T cell transfer: Molecular Therapy cell.com/molecular-ther… Great to see this collaboration now out in Molecular Therapy Fadi Issa Oliver McCallion Dimitrios L. Wagner

🚨 A bold approach to treating severe autoimmunity: We explored CRISPR-Cas9 mediated deletion of the PR3 autoantigen in blood stem cells as a strategy for ANCA-associated vasculitis. 🧬 Great idea and execution by Kettritz lab Charité - Universitätsmedizin Berlin 🔗 doi.org/10.1016/j.kint…

🔬"Approaches to target solid tumors and the tumor microenvironment with adoptive T cell therapies." Thank you Katie McKenna Ph.D. Katie McKenna, PhD for sharing your work with us! What approaches have you found effective in targeting solid tumors?📝

The recent work from the lab on mKRAS peptide-specific CAR T cells is now available online. A pipeline of new peptide-centric CARs is now in process. Stay tuned. #CAR #KRAS Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy sciencedirect.com/science/articl…

Big if true: Versatile and efficient non-viral integration of large transgenes in human T cells via CRISPR knock-in and engineered integrases biorxiv.org/content/10.110…

Versatile and efficient non-viral integration of large transgenes in human T cells via CRISPR knock-in and engineered integrases biorxiv.org/content/10.110…

“Versatile and efficient non-viral integration of large transgenes in human T cells via CRISPR knock-in and engineered integrases" Kassing I, Kath J [..] Wagner DL. bioRxiv. 2025-09-11 (preprint). doi.org/10.1101/2025.0… 8 kb KI: ... outperforms HDR & PASSIGE by 19-fold & 5-fold

Yeah. Targeted multi-gene delivery in primary T cells! Use case: 2 CARs + safety switch -> dual antigen targeting in lymphoma to overcome antigen escape. Best part: that’s our preprint :D

Exciting news 🎉 BMJ Immunology is now open for submissions! As Editor in Chief, I’m proud to launch this new home for cutting-edge immunology research. Explore and submit here 👉 bmjimmunology.bmj.com

HLA matching or CRISPR editing HLA-I/II enables engraftment & function of allo human Treg therapy in a humanized mouse transplantation model Nature Communications Dimitrios L. Wagner Oliver McCallion Weijie Du Viktor Glaser Fadi Issa 🇬🇧🇩🇪🇺🇸 nature.com/articles/s4146…

We're excited to share our latest research, published in Nature Communications. Engineering "off the shelf" Tregs for use in transplantation. A great collaboration with our colleagues in Berlin. rdcu.be/eKZRk

BIG ANNOUNCEMENT📣: I haven’t been this excited to be part of something new in 15 years… Thrilled to reveal the passion project I’ve been working on for the past year and a half!🙀🥳 It started from my frustration with the depressing effect that the current publishing system has

@nba it’s really annoying that even if you pay for the league pass app you are forced to watch 30 seconds of commercials (for the very same league pass App that I already paid for!) every time you want to watch 2 minutes of highlights